<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862978</url>
  </required_header>
  <id_info>
    <org_study_id>MTSVKNEUROL001</org_study_id>
    <nct_id>NCT01862978</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke</brief_title>
  <acronym>Heparinas</acronym>
  <official_title>Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Martin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Martin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to show the efficacy and safety of heparin and nadroparin in the&#xD;
      acute phase of ischemic stroke. Therapeutic agents are administered at intervals of 4.5 to 2&#xD;
      hours after onset of clinical signs. Overall administration of anticoagulant agents will test&#xD;
      72 hours.&#xD;
&#xD;
      Randomized patients will be divided into three groups. The first group of patients will&#xD;
      receive heparin intravenously at the beginning of 2500 UI bolus intravenously, followed by&#xD;
      intravenous pump 1000 UI / h (18-20 IU / kg / hr) to reach 2-2.5 times the baseline aPTT.&#xD;
      After 24 hours, patients will receive the group Nadroparin subcutaneously in the therapeutic&#xD;
      dose.&#xD;
&#xD;
      Second group of patients will be administered subcutaneously Nadroparin the therapeutic dose&#xD;
      as recommended.&#xD;
&#xD;
      The third group of patients are those who will receive placebo intravenously and 24 hours&#xD;
      after receiving nadroparin subcutaneously in the therapeutic dose.&#xD;
&#xD;
      All patients will receive after 24 hours of starting treatment 100 mg of aspirin per orally.&#xD;
&#xD;
      For initiation of treatment will be assessed:&#xD;
&#xD;
        -  Modified Rankin Scale, National Institutes of Health Stroke Scale, inclusion, exclusion&#xD;
           criteria&#xD;
&#xD;
        -  Sign the informed consent and patient randomization&#xD;
&#xD;
        -  Laboratory parameters: glucose, creatinine, GGT, K, Na, Cl, blood count, basic&#xD;
           coagulation&#xD;
&#xD;
        -  Women of childbearing age (pregnancy test)&#xD;
&#xD;
        -  History, clinical presentation, medical history, basic internal review of the status&#xD;
           (blood pressure, pulse, body temperature, etc.).&#xD;
&#xD;
        -  Initial CT examination of the brain&#xD;
&#xD;
        -  EKG&#xD;
&#xD;
        -  USG sections of extracranial carotid and vertebral arteries&#xD;
&#xD;
        -  special hematology factors&#xD;
&#xD;
      If a patient meets all the necessary criteria, he may be given the test substance. During the&#xD;
      first 24 hours will be monitored at regular intervals vital functions.&#xD;
&#xD;
      After 24 hours, each patient received subcutaneous Nadroparin the therapeutic dose and also&#xD;
      100 mg of aspirin per orally.&#xD;
&#xD;
      In the interval from 24 to 30 hours of starting treatment the patient will be made:&#xD;
&#xD;
        -  Control CT brain&#xD;
&#xD;
        -  EKG&#xD;
&#xD;
        -  Basic coagulation&#xD;
&#xD;
        -  Reduction to stop treatment for newly identified haemorrhage or severe and extensive&#xD;
           focal cerebral ischemia by CT scan&#xD;
&#xD;
        -  special hematology factors&#xD;
&#xD;
           72 hours, 7, 30 and 90 days after starting treatment, the patient's clinical evaluation&#xD;
           using the Modified Rankin Scale, National Institutes of Health Stroke Scale and Barthel&#xD;
           Index.&#xD;
&#xD;
      Safety endpoints: mortality, adverse side effects, bleeding&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of nadroparine or heparin</measure>
    <time_frame>DAY 3,7,30,90</time_frame>
    <description>Safety - incidence of intracranial hemorhage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of nadroparine or heparin</measure>
    <time_frame>DAY 3,7, 30, 90</time_frame>
    <description>Efficacy -level of improvement measured by mRS, and NIHSS</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receiving Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nadroparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receiving nadroparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin</intervention_name>
    <arm_group_label>Nadroparin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_label>Nadroparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ischemic stroke&#xD;
&#xD;
          -  female or male gender&#xD;
&#xD;
          -  mRS (modified Rankin Scale) 0-1 (min one month before the event)&#xD;
&#xD;
          -  NIHSS ≥ 6 and ≤ 25&#xD;
&#xD;
          -  Age: 18-80 years&#xD;
&#xD;
          -  initiation of therapy in the interval from 4.5 to 24 hours from onset of symptoms of&#xD;
             ischemic stroke&#xD;
&#xD;
          -  focal neurological deficit of at least 30 min, which was significantly obviously does&#xD;
             not disappear before treatment&#xD;
&#xD;
          -  patient will participate voluntarily and signed informed consent. Informed consent&#xD;
             will be obtained from each patient, guardian or close relative&#xD;
&#xD;
          -  patients who are unable to sign, but who are able to understand what means to&#xD;
             participate in the study, may give informed consent through eyewitness&#xD;
&#xD;
          -  willingness and ability to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intracranial hemorrhage confirmed by CT scan&#xD;
&#xD;
          -  CT image heavy and extensive focal cerebral ischemia&#xD;
&#xD;
          -  lacunar syndrome&#xD;
&#xD;
          -  epileptic seizure at the beginning of ischemic stroke&#xD;
&#xD;
          -  previous or planned treatment with intravenous, intra-arterial thrombolysis,&#xD;
             mechanical recanalization or ultrasound assisted thrombolysis&#xD;
&#xD;
          -  stroke, myocardial infarction, head trauma in the last 3 months&#xD;
&#xD;
          -  tromboctov count below 100 000/mm ³&#xD;
&#xD;
          -  therapeutically uncontrolled blood pressure: systolic blood pressure&gt; 185 mmHg or&#xD;
             diastolic blood pressure&gt; 110 mmHg&#xD;
&#xD;
          -  therapeutically uncontrolled blood glucose ˂ 2.77 or&gt; 22.15 mmol / l&#xD;
&#xD;
          -  Known bleeding diathesis, other coagulopathies, severe hepatopathy, severe nephropathy&#xD;
&#xD;
          -  patients receiving oral anticoagulants&#xD;
&#xD;
          -  current or previous life-threatening bleeding&#xD;
&#xD;
          -  major surgery less than 2 weeks ago&#xD;
&#xD;
          -  known malignancy&#xD;
&#xD;
          -  active TB&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  allergy to Heparin or Fraxiparine&#xD;
&#xD;
          -  known alcohol abuse and / or drugs&#xD;
&#xD;
          -  active participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Nosal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessenius Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Egon Kurca, MD, PhD, prof</last_name>
    <role>Study Director</role>
    <affiliation>Jessenius Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Nosal, MD, PhD</last_name>
    <phone>+421905764991</phone>
    <email>vnosal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jana Dluha, MD</last_name>
    <phone>+421905514377</phone>
    <email>jana.dluha@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurology Clinic Univeristy Hospital in Martin</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Dluha, MD</last_name>
      <phone>+421905514377</phone>
      <email>jana.dluha@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Nosal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Egon Kurca, MD,PhD,prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jana Dluha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Sivak, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jozef Michalik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ema Kantorova, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milan Grofik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milan Kratky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kubisz, MD,DSc,prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Chudy, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Duraj, Mgr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jela Ivankova, RNDr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Martin</investigator_affiliation>
    <investigator_full_name>Vladimir Nosal, MD, PhD</investigator_full_name>
    <investigator_title>Prof.assistant</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Heparin</keyword>
  <keyword>Nadroparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

